Tag: Lucentis
Repeated Ranibizumab Doesn’t Impair Macular Perfusion
Findings in patients with diabetic macular edema who completed 36 months of RESTORE study
Aflibercept, Ranibizumab Not Cost-Effective Vs. Bevacizumab
Not cost-effective for diabetic macular edema unless prices decrease considerably
AAO: Ranibizmab Noninferior to Panretinal Photocoagulation
Among eyes with proliferative diabetic retinopathy, ranibizumab noninferior at two years
Study: No Higher Eye Infection Risk With Bevacizumab
Rates of endophthalmitis were 0.017 percent for bevacizumab and 0.025 percent for ranibizumab
